# Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar

> **NCT02461186** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **University of Oxford**

## Conditions studied

- Uncomplicated Falciparum Malaria
- Artemisinin-resistant

## Interventions

- **DRUG:** Arterolane maleate-piperaquine phosphate (Synriam)
- **DRUG:** Dihydroartemisinin-piperaquine phosphate (Duocotexin)

## Key facts

- **NCT ID:** NCT02461186
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change of the study site due to the current political climate in Myanmar.
- **Last updated:** 2015-11-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461186, "Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02461186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*